Clinical Trials for Non-Small Cell Lung Cancer

A Phase 1, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109 for the Treatment of Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial is for adult patients with advanced or metastatic non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, or malignant melanoma who have no remaining standard treatment options, and it evaluates the safety, tolerability, and dosing of the investigational drug LB-LR1109, administered intravenously.

ClinicalTrials.gov ID: NCT06332755

A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced solid malignancies, such as NSCLC, MSS CRC, PDAC, G/GEJC, and SCCHN, evaluating the safety and tolerability of BMS-986484, an investigational biologic potentially targeting fibroblast activation protein, as monotherapy and in combination with the PD-1 inhibitor nivolumab.

ClinicalTrials.gov ID: NCT06544655

A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients aged 18-72 with advanced, chemotherapy-refractory non-small cell lung cancer (NSCLC), assessing the efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) therapy combined with aldesleukin after a lymphodepleting regimen of cyclophosphamide and fludarabine, with the aim of leveraging the immune system to induce tumor regression.

ClinicalTrials.gov ID: NCT02133196

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of FWD1509 MsOH in Advanced Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with advanced NSCLC featuring EGFR or HER2 mutations, who have progressed on or are intolerant to existing therapies, and investigates FWD1509 MsOH, an oral tyrosine kinase inhibitor targeting EGFR and HER2 mutations, including exon 19 deletions, L858R, T790M, and EGFRex20ins.

ClinicalTrials.gov ID: NCT05068024

A Phase 1b Open-Label, Dose-Escalation, Safety, and Pharmacodynamic Study of Minnelide™ Capsules Given in Combination With Osimertinib in Patients With EGFR Mutated NSCLC

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial is for patients with advanced EGFR-mutated NSCLC, specifically those with Ex19del or L858R mutations, who have progressed after osimertinib monotherapy. It investigates the safety and efficacy of combining minnelide, a triptolide analog that disrupts heat shock protein pathways, with the EGFR TKI osimertinib.

ClinicalTrials.gov ID: NCT05166616

A Phase 1/2 Study of TAS3351 in Patients With Advanced Non-Small Cell Lung Cancer and EGFR Mutations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial investigates TAS3351, a novel fourth-generation EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic non-small cell lung cancer harboring an acquired C797S EGFR mutation and a performance status of 0 or 1, excluding those with significant cardiac conditions or unstable CNS metastases. TAS3351 targets EGFR mutations including resistance variations T790M and C797S while sparing wild-type EGFR, with potential brain-penetrating properties.

ClinicalTrials.gov ID: NCT05765734

A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial involves patients with unresectable, locally advanced, or metastatic solid tumors or lymphomas who have not responded to standard treatments and investigates IMT-009, a monoclonal antibody targeting CD161 on NK and T cells, administered as monotherapy and combined with fruquintinib, a VEGFR kinase inhibitor. Key cancers studied include non-small cell lung cancer, head and neck carcinoma, and diffuse large B cell lymphoma.

ClinicalTrials.gov ID: NCT05565417

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates STX-721, an oral tyrosine kinase inhibitor targeting EGFR and HER2 exon 20 insertion mutations, in adult patients with locally advanced or metastatic non-small cell lung cancer who have already undergone treatments such as platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT06043817

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls patients with advanced or recurrent HER2-positive solid tumors who have progressed after prior treatments, testing XMT-2056, an antibody-drug conjugate that binds to a novel HER2 epitope and delivers a STING agonist to stimulate immune responses.

ClinicalTrials.gov ID: NCT05514717

An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Zeta Inhibitor (DGKzi) BAY 2965501 as Monotherapy, and in Combination, in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls patients with advanced solid tumors, including non-small cell lung cancer and gastric adenocarcinoma, to evaluate the safety and efficacy of BAY2965501, a DGKζ inhibitor targeting diacylglycerol kinases to enhance T-cell-mediated anti-tumor activity, both as monotherapy and in combination with pembrolizumab and platinum-based chemotherapy. Participants must have an ECOG performance status of 0-1 and meet specific disease criteria, with exclusions for primary CNS malignancies or uncontrolled brain metastases.

ClinicalTrials.gov ID: NCT05614102